About the Authors
- Okjae Lim
-
Affiliations BioMedical Science and Engineering Interdisciplinary Program, KAIST, Daejeon, Republic of Korea, Cell Therapy Team, Mogam Biotechnology Research Institute, Yongin, Gyeonggi-do, Republic of Korea, Laboratory of Immunology and Infectious Diseases, Graduate School of Medical Science and Engineering, KAIST, Daejeon, Republic of Korea
- Yuna Lee
-
Affiliation Cell Therapy Team, Mogam Biotechnology Research Institute, Yongin, Gyeonggi-do, Republic of Korea
- Hyejin Chung
-
Affiliation Cell Therapy Team, Mogam Biotechnology Research Institute, Yongin, Gyeonggi-do, Republic of Korea
- Jung Hyun Her
-
Affiliation Cell Therapy Team, Mogam Biotechnology Research Institute, Yongin, Gyeonggi-do, Republic of Korea
- Sang Mi Kang
-
Affiliation Cell Therapy Team, Mogam Biotechnology Research Institute, Yongin, Gyeonggi-do, Republic of Korea
- Mi-young Jung
-
Affiliation Cell Therapy Division, Green Cross LabCell Corp., Yongin, Gyeonggi-do, Republic of Korea
- Bokyung Min
-
Affiliation Cell Therapy Team, Mogam Biotechnology Research Institute, Yongin, Gyeonggi-do, Republic of Korea
- Hyejin Shin
-
Affiliation Cell Therapy Division, Green Cross LabCell Corp., Yongin, Gyeonggi-do, Republic of Korea
- Tae Min Kim
-
Affiliation Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea
- Dae Seog Heo
-
Affiliation Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea
- Yu Kyeong Hwang
-
* E-mail: ykhwang@mogam.re.kr (YKH); ecshin@kaist.ac.kr (ECS)
Affiliation Cell Therapy Team, Mogam Biotechnology Research Institute, Yongin, Gyeonggi-do, Republic of Korea
- Eui-Cheol Shin
-
* E-mail: ykhwang@mogam.re.kr (YKH); ecshin@kaist.ac.kr (ECS)
Affiliations BioMedical Science and Engineering Interdisciplinary Program, KAIST, Daejeon, Republic of Korea, Laboratory of Immunology and Infectious Diseases, Graduate School of Medical Science and Engineering, KAIST, Daejeon, Republic of Korea
Competing Interests
Eui-Cheol Shin is a PLOS ONE Editorial Board member, and understands that this does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials. The authors have read the journal's policy and have the following conflicts: MJ and HS are employed in Green Cross LabCell Corp. Mogam Biotechnology Research Institute is a non-profit research foundation. Patent Number: KR2008-74069. Date Patent Issued: March 28, 2012. Title of Patent: Growth method for natural killer cells. Assignee: Green Cross LabCell Corp. and Seoul National University Hospital. Inventor: Mi-young Jung, Dae Seog Heo, and Yu Kyeong Hwang. Patent Number: JP2011-521023. Date Patent Filed: January 31, 2011. Title of Patent: Growth method for natural killer cells. Assignee: Green Cross LabCell Corp. and Seoul National University Hospital. Inventor: Mi-young Jung, Dae Seog Heo, and Yu Kyeong Hwang. Patent Number: CN200980130121.5. Date Patent Filed: January 30, 2011. Title of Patent: Growth method for natural killer cells. Assignee: Green Cross LabCell Corp. and Seoul National University Hospital. Inventor: Mi-young Jung, Dae Seog Heo, and Yu Kyeong Hwang. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials. The other authors declare that they have no conflict of interest.
Author Contributions
Conceived and designed the experiments: OL YL HC JHH SMK MYJ TMK DSH YKH ECS. Performed the experiments: OL YL HC JHH SMK MYJ BM HS. Analyzed the data: OL YL JHH ECS. Wrote the paper: OL YKH ECS.